50780-50-2

Basic information

• Product Name: CHLOROMETHYL (4-NITROPHENYL) CARBONATE
• Synonyms: CHLOROMETHYL (4-NITROPHENYL) CARBONATE
• CAS NO: 50780-50-2
• Molecular Formula: C₈H₆ClNO₅
• Molecular Weight: 231.59
• Mol File: 50780-50-2.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CHLOROMETHYL (4-NITROPHENYL) CARBONATE(CAS DataBase Reference)
• NIST Chemistry Reference: CHLOROMETHYL (4-NITROPHENYL) CARBONATE(50780-50-2)
• EPA Substance Registry System: CHLOROMETHYL (4-NITROPHENYL) CARBONATE(50780-50-2)

Safety Data

• Hazardous Substances Data: 50780-50-2(Hazardous Substances Data)

Upstream product

• 109-02-4 4-methyl-morpholine 
• 100-02-7 4-nitro-phenol 
• 22128-62-7 carbonochloridic acid, chloromethyl ester 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 100-02-7 4-nitro-phenol 
• 99068-88-9 p-nitrophenyl N-iso-propylcarbamate 
• 170097-82-2 benzoic acid 4-nitrophenoxycarbonyloxymethyl ester 
• 101623-83-0 2,2-dimethylpropionyloxymethyl p-nitrophenyl carbonate 
• 194995-44-3 2-methylpropionic acid 4-nitro-phenoxycarbonyloxymethyl ester 
• 3655-05-8 tert-butoxycarbonylglycine p-nitrophenylester 
• 1541195-54-3 (bis(benzyloxy)phosphoryloxy)methyl 4-nitrophenylcarbonate 
• 1427046-45-4 carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester 4-nitrophenyl ester 
• 1350836-93-9 C₁₆H₁₃N₅O₅ 
• 1350836-83-7 C₁₆H₁₃N₅O₅ 
• 101623-70-5 acetic acid 4-nitro-phenoxycarbonyl-oxymethyl ester 
• 194995-45-4 butyryloxymethyl p-nitrophenyl carbonate 
• 132906-07-1 chloromethyl N-benzyl carbamate 

Relevant articles and documents

Macrocyclic prodrugs of a selective nonpeptidic direct thrombin inhibitor display high permeability, efficient bioconversion but low bioavailability

The only oral direct thrombin inhibitors that have reached the market, ximelagatran and dabigatran etexilat, are double prodrugs with low bioavailability in humans. We have evaluated an alternative strategy: the preparation of a nonpeptidic, polar direct

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.

(3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10

The compounds are intermediates in the preparation of therapeutic agents useful in the treatment of viral infections, particularly HIV infection. The compounds are (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenylmethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10.